Press releases

To stay up to date with our development, sign up for a subscription.


Notice of Annual General Meeting in Sedana Medical


The board of directors of Sedana Medical AB (publ) has resolved to convene an annual general meeting of shareholders to be held Wednesday, 22 May 2024. Further details on the proposals can be found in the notice convening the meeting, below. The not…

Sedana Medical publishes its Annual Report for 2023


Sedana Medical AB (publ) publishes its Annual Report for 2023. The Annual Report describes important events and financial information for 2023, as well as the progress the company has made on its strategic priorities during the year.

Sedana Medical files submission for paediatric indication


Sedana Medical AB (publ) announces that the company has submitted a Type II variation with the aim of including the paediatric population (3-17 years) into the existing Sedaconda[®] indication for inhaled sedation of mechanically ventilated patients…

Sedana Medical’s Nomination Committee established


According to the principles for the appointment of the Nomination Committee in Sedana Medical AB (publ), the Nomination Committee for the Annual General Meeting 2024 shall be composed of members appointed by the three largest shareholders as of Septe…

The SESAR investigator-initiated trial completes patient enrollment


Sedana Medical AB (publ) today announces that the enrollment of the planned 700 patients in the SESAR trial has been completed. The trial Sevoflurane for Sedation in Acute Respiratory Distress Syndrome: A Multicenter Prospective Randomized Trial (SES…

Sedana Medical receives market approval in the UK


The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Sedana Medical AB (publ) marketing authorization for the company’s pharmaceutical product Sedaconda[®] (isoflurane) in the United Kingdom.

Sedana Medical receives US patent for Sedaconda ACD-S


Sedana Medical AB (publ) announces that the US Patent and Trademark Office (USPTO) has granted Sedana Medical a patent for the medical device Sedaconda ACD-S (US Patent No. 11,707,593 B2). The patent will run until 2037.

Sedana Medical’s CEO and CFO acquire shares in the company


Sedana Medical AB’s (publ) CEO Johannes Doll and CFO Johan Spetz have each acquired 100,000 shares in the company from the founders Ola Magnusson and Sten Gibeck. The transactions were done on 25 September 2023 at a price of SEK 18 per share, corresp…